Login to Your Account

Biocryst's cohort add-on meaning sparks debate on Dyax

By Randy Osborne
Staff Writer

Friday, August 7, 2015

As part of its second quarter earnings report, Biocryst Pharmaceuticals Inc. said it was adding a 14-day treatment cohort to its phase I study in healthy volunteers of kallikrein inhibitor BCX7353, intended as a next-generation, once-daily HAE therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription